Brief: Acer Therapeutics Reports Q3 2022 Financial Results
14/11/2022 22:42
Nov 14 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS REPORTS Q3 2022 FINANCIAL RESULTS AND
PROVIDES
CORPORATE UPDATE
* ACER THERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE
$6.4
MILLION AS OF SEPTEMBER 30, 2022, COMPARED TO $12.7 MILLION AS
OF DECEMBER 31, 2021
* ACER THERAPEUTICS INC - NET LOSS FOR THREE MONTHS ENDED
SEPTEMBER 30, 2022 WAS $5.0 MILLION, OR $0.31 NET LOSS PER SHARE
Source text for Eikon: ID:nGNX6PHmDX
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31